Abstract
Bisphosphonates are the cornerstone for the management of multiple myeloma bone disease. Several international organisations recommend the use of bisphosphonates in patients with newly diagnosed myeloma and bone disease (presence of lytic lesions as shown with conventional radiography or diffuse osteoporosis due to myeloma) for 2 years and for those who relapse.1,2 In the USA, intravenous zoledronic acid and pamidronic acid are used in the treatment of multiple myeloma, whereas in some European countries oral clodronic acid has also been licensed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
